{"id":"W3013704572","doi":"10.1158/1538-7445.sabcs19-pd4-01","title":"Abstract PD4-01: First-line veliparib plus carboplatin/paclitaxel in patients with HER2-negative advanced/metastatic g<i>BRCA</i>-associated breast cancer: Planned subgroup analysis from the phase 3 BROCADE3 trial","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Internal medicine; Metastatic breast cancer; Carboplatin; PARP inhibitor; Placebo; Breast cancer; Hazard ratio; Population; Oncology; Clinical endpoint; Cancer; Chemotherapy; Surgery; Randomized controlled trial; Confidence interval; Pathology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002328239,0.001299379,0.002855675,0.0005029754,0.0002618096,0.001388228,0.0007356012,0.0007706011,0.003914154],"category_scores_gemma":[0.00152151,0.0004229352,0.005955006,0.0005615451,0.0004391372,0.000575427,0.0004538322,0.002257206,0.0003670078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009374628,"about_ca_system_score_gemma":0.001005636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008485136,"about_ca_topic_score_gemma":0.002438362,"domain_scores_codex":[0.999074,0.0005280228,0.00008478827,0.000134512,0.00007132728,0.0001072812],"domain_scores_gemma":[0.9994245,0.0002000312,0.0001572329,0.00006153206,0.00004013066,0.0001165996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9492778,0.001050073,0.004850378,0.001400781,0.01907131,0.00009924691,0.0000378825,0.001137021,0.003277801,0.00009273451,0.001233279,0.01847174],"study_design_scores_gemma":[0.8937403,0.05084563,0.02113022,0.0001903528,0.02799893,0.0002134399,0.00007946663,0.00148212,0.001561452,0.0005059651,0.002198888,0.00005314849],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9661344,0.02342977,0.0009890913,0.0009340832,0.0004062284,0.002044203,0.003568055,0.0001207469,0.00237342],"genre_scores_gemma":[0.9913,0.003249207,0.0005753386,0.000594252,0.0002126397,0.000889688,0.001966441,0.00001900631,0.001193449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003914154,"threshold_uncertainty_score":0.01309413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06192788902987865,"score_gpt":0.3858429995150197,"score_spread":0.323915110485141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}